Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments

• US 5,733,548 A
• Filed: 06/05/1995
• Issued: 03/31/1998
• Est. Priority Date: 03/17/1993
• Status: Expired due to Term

• Current Assignee: Government of the United States of America, The United States of America As Represented By The Secretary of Agriculture
• Original Assignee: United States Department Of Health And Human Services
• Inventors: Bennink, Jack R., Rosenberg, Steven A., Restifo, Nicholas P., Bacik, Igor, Yewdell, Jonathan W.
• Primary Examiner(s): Elliott, George C.
• Assistant Examiner(s): SCHWARTZMAN, ROBERT A
• Application Number:
  US08/464,318
• Time in Patent Office: 1,030 Days
• Field of Search: 424/184.1, 424/192.1, 424/185.1, 424/204.1, 424/234.1, 424/265.1, 424/277.1, 435/69.1, 435/69.3, 514/2, 530/300, 530/328, 530/329
• US Class Current: 424/184.1
• CPC Class Codes: A61K 2039/5158 Antigen-pulsed cells, e.g. T-cells
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 2239/38 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2239/46 characterised by the cancer treated
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/145 Orthomyxoviridae, e.g. influenza virus
• CPC Class Codes: A61K 39/205 Rhabdoviridae, e.g. rabies virus
• CPC Class Codes: A61K 39/461 characterised by the cell type used
• CPC Class Codes: A61K 39/4644 Cancer antigens
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/77 : Ovalbumin
• CPC Class Codes: C07K 2319/00 : Fusion polypeptide
• CPC Class Codes: C07K 2319/04 : containing an ER retention signal such as a C-terminal HDEL motif
• CPC Class Codes: C07K 2319/40 : containing a tag for immunodetection, or an epitope for immunisation
• CPC Class Codes: C12N 15/625 : containing a sequence coding for a signal sequence
• CPC Class Codes: C12N 2710/24143 : viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2760/16134 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2760/20122 : New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2760/20134 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Immunogenic chimeric proteins comprising an endoplasmic reticulum signal sequence and at least one other peptide are disclosed. The invention relates to the design of vaccinia virus constructs capable of directing host organism synthesis of immunogenic chimeric proteins which can be used as immunogens, as vaccines, or in methods of treatment for cancer, infectious diseases, or autoimmune diseases.

Claims

1. An immunogenic chimeric protein comprising:

(a) an endoplasmic reticulum signal sequence peptide; and

(b) at least one other peptide, where said other peptide forms a complex with class I MHC molecules.

2. The chimeric protein according to claim 1, wherein said endoplasmic reticulum signal sequence peptide has a sequence according to SEQ. ID NO:

1.

3. The chimeric protein according to claim 1, wherein said other peptide is a tumor peptide.

4. The chimeric protein according to claim 1, wherein said other peptide is a bacterial peptide.

5. The chimeric protein according to claim 1, wherein said other peptide is a parasitic peptide.

6. The chimeric protein according to claim 1, wherein said other peptide is an autoimmune disease peptide.

7. A method of producing a T cell response in a mammal comprising administering the chimeric protein of claim 1 to said mammal in an amount effective to elicit said T cell response.

8. A method of producing a T cell response in a mammal comprising administering the chimeric protein of claim 2 to said mammal in an amount effective to elicit said T cell response.

9. A method of producing a T cell response in a mammal comprising administering the chimeric protein of claim 3 to said mammal in an amount effective to elicit said T cell response.

10. A method of producing a T cell response in a mammal comprising administering the chimeric protein of claim 4 to said mammal in an amount effective to elicit said T cell response.

11. A method of producing a T cell response in a mammal comprising administering the chimeric protein of claim 5 to said mammal in an amount effective to elicit said T cell response.

12. A method of producing a T cell response in a mammal comprising administering the chimeric protein of claim 6 to said mammal in an amount effective to elicit said T cell response.

13. An immunogenic chimeric protein comprising:

(a) an endoplasmic reticulum signal sequence peptide; and

(b) a viral peptide having an amino acid sequence selected from the group consisting of SEQ ID NO;

2, SEQ ID NO;

3 and SEQ ID NO;

4.

14. The chimeric protein according to claim 13 wherein said endoplasmic reticulum signal sequence peptide has a sequence according to SEQ ID NO:

1.

15. A method of producing a T cell response in a mammal comprising administering the chimeric protein of claim 13 to said mammal in an amount effective to elicit said T cell response.

16. A method of producing a T cell response in a mammal comprising administering the chimeric protein of claim 14 to said mammal in an amount effective to elicit said T cell response.